Stock comparison
IDEXX Laboratories
Vertex Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
VRTX
Vertex Pharmaceuticals
Market cap
$110.28B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | VRTX | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 64C | IDXX |
| Benjamin Graham | 80A | 66D | IDXX |
| Philip Fisher | 75B | 70B | IDXX |
| Peter Lynch | 71B | 60C | IDXX |
| Joel Greenblatt | 83C | 55C | IDXX |
| Charlie Munger | 87A | 67D | IDXX |
| Terry Smith | 84A | 64C | IDXX |
Side-by-side metrics
| Metric | IDXX | VRTX |
|---|---|---|
| Market cap | $44.12B | $110.28B |
| P/E (TTM) | 39.0x | 25.6x |
| EV/EBIT | 31.6x | 22.6x |
| ROIC (TTM) | 40.66% | 17.74% |
| Gross margin | 62.05% | 86.28% |
| Net margin | 24.63% | 35.4% |
| Revenue CAGR 5y | 7.56% | 12.37% |
| EPS CAGR 5y | 10.79% | 14.2% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 17.74%+56%
VRTX leads on
- Debt / Equity0.1xvs 0.7x+85%
- Market cap$110.28Bvs $44.12B+60%
- Revenue CAGR 5y12.37%vs 7.56%+39%
- P/E (TTM)25.6xvs 39.0x+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.